Leveraging the natural tolerance induction capabilities of the liver

Topas Therapeutics is focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities, targeting liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas Particle Conjugates mimic such bloodborne antigens and follow their natural processing in LSECs, including the generation of long-lasting antigen-specific regulatory T cells (Tregs), a critically important type of immune cell for maintaining immune tolerance. Topas’ novel technology is enabling the development of new therapeutic solutions for challenging diseases.

Latest News

2018-09-27 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

read more …

2018-04-24 – Press release

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

read more …

2018-01-25 – Press release

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

read more …